ELOC

Elongin-C · Q15369 · ELOC on Sugi Atlas →

37,685 patent compounds predicted against ELOC, 28,653 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15110355 SCHEMBL15110355 0.83 15/20
SCHEMBL15112002 SCHEMBL15112002 0.83 15/20
SCHEMBL15110402 SCHEMBL15110402 0.79 14/20
SCHEMBL15110438 SCHEMBL15110438 0.75 14/20
SCHEMBL15110445 SCHEMBL15110445 0.75 14/20
SCHEMBL15110331 SCHEMBL15110331 0.57 13/20
SCHEMBL15110221 SCHEMBL15110221 0.56 13/20
SCHEMBL15110257 SCHEMBL15110257 0.80 12/20
SCHEMBL15110329 SCHEMBL15110329 0.79 12/20
SCHEMBL15112608 SCHEMBL15112608 0.79 12/20
SCHEMBL15110281 SCHEMBL15110281 0.74 12/20
SCHEMBL15112677 SCHEMBL15112677 0.70 12/20
SCHEMBL15125829 SCHEMBL15125829 0.70 12/20
SCHEMBL15112661 SCHEMBL15112661 0.65 12/20
SCHEMBL15110112 SCHEMBL15110112 0.64 12/20
SCHEMBL15110424 SCHEMBL15110424 0.61 12/20
SCHEMBL15110391 SCHEMBL15110391 0.60 12/20
SCHEMBL15110317 SCHEMBL15110317 0.54 12/20
SCHEMBL15110166 SCHEMBL15110166 0.49 12/20
SCHEMBL15110047 SCHEMBL15110047 0.47 12/20

Clinical trials — most relevant to ELOC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Research on the Early and Prognosis Diagnosis of Vascular Dementia nanRECRUITING
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks nanRECRUITING
Impact of Elastin Mediated Vascular Stiffness on End Organs nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate nanCOMPLETED
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank nanCOMPLETED
Genomic Translation for Amyotrophic Lateral Sclerosis Care nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME) nanCOMPLETED
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma nanRECRUITING
Corpus Callosum Agenesis and Intellectual Disability nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Mutational Landscape in Hepatocellular Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ELOC binder may also engage these)

ProteinNameSimilarity
Q2KII4 1.000 Q2KII4 →
P83941 1.000 P83941 →
P83940 1.000 P83940 →
Q9USX9 0.971 Q9USX9 →
Q03071 0.971 Q03071 →
B8NSJ0 0.968 B8NSJ0 →
Q54Q05 0.968 Q54Q05 →
B6QGB9 0.968 B6QGB9 →
Q8TGW7 0.967 Q8TGW7 →
Q8NK13 0.966 Q8NK13 →
Q9Y709 0.966 Q9Y709 →
Q5KU00 0.966 Q5KU00 →
Q0CA59 0.966 Q0CA59 →
Q751F9 0.965 Q751F9 →
Q4WTT8 0.965 Q4WTT8 →
Q6H4D6 0.965 Q6H4D6 →
Q9FHW7 0.963 Q9FHW7 →
G5ECU1 0.963 G5ECU1 →
D4ARL8 0.962 D4ARL8 →
Q9LNT9 0.962 Q9LNT9 →
Q557E4 0.962 Q557E4 →
O65674 0.962 O65674 →
A1CZG3 0.961 A1CZG3 →
B0Y3B5 0.961 B0Y3B5 →
A1C9U5 0.961 A1C9U5 →
B8MDP8 0.960 B8MDP8 →
Q6PL11 0.960 Q6PL11 →
Q96Q07 0.959 Q96Q07 →
Q5BAX8 0.959 Q5BAX8 →
Q651E8 0.959 Q651E8 →